Recruitment

Recruitment Status
Completed
Estimated Enrollment
Same as current

Summary

Conditions
  • Diabetic Macular Edema
  • Non Proliferative Diabetic Retinopathy
  • Proliferative Diabetic Retinopathy
Type
Interventional
Phase
Phase 2
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular edema and prior treatment with ? 2 intravitreal anti-VEGF injections.

This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular edema and prior treatment with ? 2 intravitreal anti-VEGF injections.

Tracking Information

NCT #
NCT01571232
Collaborators
Allergan
Investigators
Principal Investigator: Ron P Gallemore, M.D, Ph.D Retina Macula Institute